LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hematologic Complications with Age in Shwachman-Diamond Syndrome

By LabMedica International staff writers
Posted on 24 Jan 2022
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Shwachman-Diamond syndrome (SDS) is a rare, inherited bone marrow failure, characterized by a low number of white blood cells, poor growth due to difficulty absorbing food, exocrine pancreatic dysfunction, and, in some cases, skeletal abnormalities.

Children with SDS have a small but significant chance of developing blood disorders such as myelodysplastic syndrome (MDS) or leukemia. Nearly 5% of children with the condition will develop leukemia, with the risk rising to 25 % by adulthood. In addition, recurring infections, including pneumonia, ear, and skin infections, are common.

A large team of medical scientists led by those at Harvard Medical School (Boston, MA, USA) conducted a cohort study of 153 subjects from 143 families with confirmed biallelic SBDS mutations enrolled on the North American Shwachman Diamond Registry or Bone Marrow Failure Registry. The team collected longitudinal complete blood counts (CBCs). CBCs were included until the time of myelodysplasia (MDS) or leukemia diagnosis or until the time of hematopoietic stem cell transplant (HSCT), when applicable.

Hemoglobin values were excluded during periods of red cell transfusions, platelet values were excluded during platelet transfusions, and absolute neutrophil counts (ANCs) were excluded while on granulocyte colony-stimulating factor (G-CSF). Local bone marrow aspirate and biopsy reports were examined for reported cellularity (from biopsies), fluorescence in situ hybridization, karyotype, and flow cytometry data. Surveillance bone marrows were defined as bone marrow examinations performed in the absence of clinical symptoms.

The investigators reported that 153 individuals (143 families) with biallelic SBDS mutations, including several short case descriptions illustrating the diversity of phenotypes in SDS. Ninety-two were male (60.1%). Median age at last follow-up was 10.4 years (range, 0.3-52.8). The cohort included 39 adults (25.5%) who were >18 years of age at the follow-up. The SBDS c.258 + 2T>C variant was present in all but one patient.

The team evaluated the association between blood counts and age, 2,146 blood counts were analyzed for 119 subjects. Absolute neutrophil counts were positively associated with age. Hemoglobin was also positively associated with age up to 18 years, but the association was negative thereafter. Platelet counts and marrow cellularity were negatively associated with age. Marrow cellularity did not correlate with blood counts. Severe marrow failure necessitating transplant developed in eight subjects at a median age of 1.7 years (range, 0.4-39.5), with 7/8 requiring transplant prior to age 8 years. Twenty-six subjects (17%) developed a myeloid malignancy (16 myelodysplasia and 10 acute myeloid leukemia) at a median age of 12.3 years (range, 0.5-45.0) and 28.4 years (range, 14.4-47.3), respectively.

The authors concluded that their study found that, although marrow cellularity decreased with age, as expected for a genetic bone marrow failure (BMF) condition, blood counts unexpectedly improved with age. Severe BMF was observed in early childhood, whereas myeloid malignancy was observed in later childhood/early adulthood. The study was published on January 11, 2022 in the journal Blood Advances.

Related Links:
Harvard Medical School

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
ESR Analyzer
TEST1 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more